JO3543B1 - تراكيب حمض أميني إصدار معدل تعطى عن طريق الفم - Google Patents

تراكيب حمض أميني إصدار معدل تعطى عن طريق الفم

Info

Publication number
JO3543B1
JO3543B1 JOP/2016/0205A JOP20160205A JO3543B1 JO 3543 B1 JO3543 B1 JO 3543B1 JO P20160205 A JOP20160205 A JO P20160205A JO 3543 B1 JO3543 B1 JO 3543B1
Authority
JO
Jordan
Prior art keywords
amino acid
modified release
orally administered
acid formulations
release orally
Prior art date
Application number
JOP/2016/0205A
Other languages
English (en)
Inventor
Reiner Alberto
Reiner Giorgio
Original Assignee
Applied Pharma Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57042912&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3543(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Applied Pharma Res filed Critical Applied Pharma Res
Application granted granted Critical
Publication of JO3543B1 publication Critical patent/JO3543B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D13/00—Finished or partly finished bakery products
    • A21D13/80—Pastry not otherwise provided for elsewhere, e.g. cakes, biscuits or cookies
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
    • A21D2/24—Organic nitrogen compounds
    • A21D2/245—Amino acids, nucleic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

يتعلق الاختراع الحالي بتوفير طرق وصيغ أحماض أمينية ذات إطلاق معدل لمعالجة أمراض أو إدارتها وهي المحددة بواسطة أيض حمض أميني مختل، بخواص حركية دوائية محسنة، وأيض محسن واستخدام محسن.
JOP/2016/0205A 2015-09-28 2016-09-25 تراكيب حمض أميني إصدار معدل تعطى عن طريق الفم JO3543B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562233695P 2015-09-28 2015-09-28

Publications (1)

Publication Number Publication Date
JO3543B1 true JO3543B1 (ar) 2020-07-05

Family

ID=57042912

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2016/0205A JO3543B1 (ar) 2015-09-28 2016-09-25 تراكيب حمض أميني إصدار معدل تعطى عن طريق الفم

Country Status (27)

Country Link
US (3) US11419837B2 (ar)
EP (2) EP4129270B1 (ar)
CN (2) CN114699397B (ar)
AR (1) AR106166A1 (ar)
AU (2) AU2016330261B2 (ar)
CA (1) CA2998276A1 (ar)
CL (1) CL2018000811A1 (ar)
CO (1) CO2018003224A2 (ar)
DK (2) DK3355856T3 (ar)
EA (1) EA038018B1 (ar)
ES (2) ES2925902T3 (ar)
HR (1) HRP20220933T1 (ar)
HU (1) HUE059603T2 (ar)
IL (3) IL285695B2 (ar)
JO (1) JO3543B1 (ar)
LT (1) LT3355856T (ar)
MX (1) MX384429B (ar)
MY (1) MY187358A (ar)
PH (1) PH12018501072A1 (ar)
PL (2) PL4129270T3 (ar)
PT (2) PT3355856T (ar)
SA (1) SA518391206B1 (ar)
SI (1) SI3355856T1 (ar)
TW (1) TWI729005B (ar)
UY (1) UY36920A (ar)
WO (1) WO2017055997A1 (ar)
ZA (1) ZA201801927B (ar)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3543B1 (ar) 2015-09-28 2020-07-05 Applied Pharma Res تراكيب حمض أميني إصدار معدل تعطى عن طريق الفم
KR102826441B1 (ko) * 2018-03-01 2025-06-26 463아이피 파트너즈, 엘엘씨 마이크로캡슐화 제품, 이의 투명한 용액, 및 제조 방법
EP3810168A1 (en) * 2018-06-20 2021-04-28 Axcella Health Inc. Methods of manufacturing amino acid compositions
US11701335B2 (en) * 2018-08-31 2023-07-18 Apr Applied Pharma Research S.A. Methods of normalizing amino acid metabolism
JP2022525339A (ja) * 2019-03-14 2022-05-12 ヘモシアー セラピューティクス，インコーポレイティド 有機酸血症の治療方法
MX2021012789A (es) * 2019-04-19 2022-01-18 Sila S R L Producto granular a base de arginina.
IT201900013473A1 (it) * 2019-07-31 2021-01-31 Vetagro Int S R L Composizioni comprendenti amminoacidi e un ulteriore componente per l'apporto di amminoacidi ad un animale monogastrico quale uomo o maiale
JP2022553943A (ja) * 2019-10-17 2022-12-27 ハーキュリーズ エルエルシー 分散可能な徐放性組成物およびその調製方法
CN110946839A (zh) * 2019-12-31 2020-04-03 烟台万润药业有限公司 一种补充硒、维生素c的咀嚼片及其制备方法
CN111821272A (zh) * 2020-08-11 2020-10-27 河北科星药业有限公司 犬用复方氨基酸肠溶片及其制备方法
CN111956644A (zh) * 2020-08-18 2020-11-20 河北科星药业有限公司 一种犬用复方氨基酸肠溶胶囊及其制备方法
CN116531334B (zh) * 2023-01-13 2023-09-15 山东国邦药业有限公司 一种盐酸多西环素颗粒剂及其制备方法
IT202300020562A1 (it) * 2023-10-04 2025-04-04 S I I T S R L Servizio Int Imballaggi Termosaldanti Granulato a rilascio modificato di principi attivi e/o ingredienti nutrizionali
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1217365A (en) * 1967-02-23 1970-12-31 Labatt Ltd John Controlled release feed additives for ruminants
US5026721A (en) * 1989-06-05 1991-06-25 Dudrick Stanley J Amino acid nutritional supplement and regimen for enhancing physical performance through sound nutrition
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US20020004072A1 (en) * 1999-05-06 2002-01-10 Peter G. Thomas "composition providing a sustained release of l-histidine and methods of manufacture thereof"
DE10220785A1 (de) 2002-05-10 2003-11-20 Degussa Geschützte Wirkstoffzubereitungen aus Aminosäuren und Verfahren zu deren Herstellung
US20040213838A1 (en) 2003-04-24 2004-10-28 Mazer Terrence B. Medical food tablets containing free amino acids
ITFI20050215A1 (it) * 2005-10-13 2007-04-14 Valpharma Internat S P A Composizione nutrizionale a base di amminoacidi
EP1897451A1 (en) * 2006-09-08 2008-03-12 SHS International Ltd. Tasteless nutritional supplement containing free amino acids
WO2011043647A1 (en) 2009-10-09 2011-04-14 N.V. Nutricia Amino acid composition with improved dispersibility
US20120039999A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
EP2645997B1 (en) * 2010-12-02 2022-08-10 UCB Pharma GmbH Once daily formulation of lacosamide
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
CN102861011B (zh) * 2012-10-12 2014-11-05 杜博 18种氨基酸的药物组合物及制剂
US20190000126A1 (en) 2015-01-07 2019-01-03 Corr-Jensen Inc. Compositions and methods for enhancing athletic performance
JO3543B1 (ar) 2015-09-28 2020-07-05 Applied Pharma Res تراكيب حمض أميني إصدار معدل تعطى عن طريق الفم
US11701335B2 (en) 2018-08-31 2023-07-18 Apr Applied Pharma Research S.A. Methods of normalizing amino acid metabolism

Also Published As

Publication number Publication date
PH12018501072A1 (en) 2019-01-28
IL285695B2 (en) 2024-01-01
EP4129270B1 (en) 2024-09-11
US20180318244A1 (en) 2018-11-08
CN114699397B (zh) 2025-01-21
HUE059603T2 (hu) 2022-12-28
IL304732A (en) 2023-09-01
IL285695A (en) 2021-09-30
SA518391206B1 (ar) 2022-12-22
CA2998276A1 (en) 2017-04-06
PT3355856T (pt) 2022-08-09
DK3355856T3 (da) 2022-08-01
LT3355856T (lt) 2022-11-10
AU2016330261A1 (en) 2018-04-12
CN108289835A (zh) 2018-07-17
US10500180B2 (en) 2019-12-10
IL258349B (en) 2021-09-30
BR112018005943A2 (pt) 2018-10-09
US20220347142A1 (en) 2022-11-03
MX384429B (es) 2025-03-14
PL3355856T3 (pl) 2022-09-12
TW201717930A (zh) 2017-06-01
UY36920A (es) 2017-04-28
AU2022205198A1 (en) 2022-08-04
ES2925902T3 (es) 2022-10-20
EA038018B1 (ru) 2021-06-23
EP3355856A1 (en) 2018-08-08
AU2022205198B2 (en) 2024-09-19
IL285695B1 (en) 2023-09-01
US12440463B2 (en) 2025-10-14
PT4129270T (pt) 2024-10-14
MY187358A (en) 2021-09-22
CO2018003224A2 (es) 2018-07-10
AR106166A1 (es) 2017-12-20
CL2018000811A1 (es) 2019-01-18
CN108289835B (zh) 2022-04-15
EP3355856B1 (en) 2022-06-22
DK4129270T3 (da) 2024-10-28
MX2018003497A (es) 2019-12-16
HRP20220933T1 (hr) 2022-10-28
US11419837B2 (en) 2022-08-23
PL4129270T3 (pl) 2024-11-25
CN114699397A (zh) 2022-07-05
EA201890815A1 (ru) 2018-10-31
HK1254555A1 (en) 2019-07-19
SI3355856T1 (sl) 2022-10-28
ES2993275T3 (en) 2024-12-26
WO2017055997A9 (en) 2018-04-19
ZA201801927B (en) 2019-01-30
AU2016330261B2 (en) 2022-04-14
IL258349A (en) 2018-05-31
EP4129270A1 (en) 2023-02-08
US20180185311A1 (en) 2018-07-05
WO2017055997A1 (en) 2017-04-06
TWI729005B (zh) 2021-06-01

Similar Documents

Publication Publication Date Title
PH12018501072A1 (en) Modified release orally administered amino acid formulations
ZA202004764B (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
PH12017500746B1 (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
PH12018500762A1 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
MX2021010886A (es) Uso de medicamentos para disminuir la evolucion de la enfermedad de parkinson.
NZ744323A (en) Compositions comprising 15-hepe and methods of using the same
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
MX2015007945A (es) Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.
RU2014154366A (ru) Применение пробиотического штамма микроорганизма enterococcus faecium l3 для лечения нейродегенеративных заболеваний
UA93426U (uk) Композиція у вигляді гелю для лікування вугрової хвороби
UA112489C2 (uk) Спосіб лікування вугрової хвороби шкіри обличчя та спини за індріксоном
HK1227294A1 (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
UA66165U (ru) Применение витаминной композиции, которая содержит витамины С и К3, в качестве средства для лечения вирусных инфекций